Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:3:1998.
doi: 10.1038/srep01998.

Topological insulator bismuth selenide as a theranostic platform for simultaneous cancer imaging and therapy

Affiliations

Topological insulator bismuth selenide as a theranostic platform for simultaneous cancer imaging and therapy

Juan Li et al. Sci Rep. 2013.

Abstract

Employing theranostic nanoparticles, which combine both therapeutic and diagnostic capabilities in one dose, has promise to propel the biomedical field toward personalized medicine. Here we investigate the theranostic properties of topological insulator bismuth selenide (Bi2Se3) in in vivo and in vitro system for the first time. We show that Bi2Se3 nanoplates can absorb near-infrared (NIR) laser light and effectively convert laser energy into heat. Such photothermal conversion property may be due to the unique physical properties of topological insulators. Furthermore, localized and irreversible photothermal ablation of tumors in the mouse model is successfully achieved by using Bi2Se3 nanoplates and NIR laser irradiation. In addition, we also demonstrate that Bi2Se3 nanoplates exhibit strong X-ray attenuation and can be utilized for enhanced X-ray computed tomography imaging of tumor tissue in vivo. This study highlights Bi2Se3 nanoplates could serve as a promising platform for cancer diagnosis and therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Schematic representation of topological insulator bismuth selenide as a theranostic platform.
Bismuth selenide is able to perform for simultaneous X-ray CT imaging and photothermal therapy.
Figure 2
Figure 2. Characterization of Bi2Se3 nanoplates.
(a) TEM image and (b) XRD pattern of Bi2Se3.
Figure 3
Figure 3. Cell cytotoxicity and cell internalization of nanoplates.
(a) Cell viability of H22 cells after incubation with increased concentration of Bi2Se3 nanoplates. (b) ICP-MS results of H22 cells incubated with Bi2Se3 nanoplates at 37°C and 4°C. Error bars correspond to mean ± standard deviations.
Figure 4
Figure 4. Results of X-ray CT imaging in vitro and in vivo.
(a) In vitro CT images of Bi2Se3 nanoplates and Iopamidol with different concentrations. Cell analysis: H22 cells incubated without contrast agent (1), with increased concentration of Bi2Se3 nanoplates (0.02 and 0.05 mol Bi l-1 for 2 and 3, respectively). (b) CT value (HU) of Bi2Se3 nanoplates (formula image) or Iopamidol (formula image) as function of the concentration. (c) CT coronal views of a mouse following an intratumoral injection of 100 μl of Bi2Se3 nanoplates solution (0.2 mol Bi l−1) (top). The corresponding 3D rendering of in vivo CT images above (bottom). The position of tumor is marked by red circles.
Figure 5
Figure 5. Photothermal therapy in in vitro and in vivo system.
(a) Photothermal effect of pure water and Bi2Se3 nanoplates with different concentrations (a–e: 0, 5, 10, 20, 50 μg ml−1) upon the irradiation of 1 W cm−2 808 nm laser. (b) H22 cell viabilities cultured with Bi2Se3 nanoplates at different concentrations with or without laser irradiation. (c) Growth of H22 tumors in different groups of mice after treatment. The relative tumor volumes were normalized to their initial sizes. (d) Representative photos of a Bi2Se3 nanoplates-injected mouse at day 0 before PTT treatment and at day 20 after treatment. Error bars correspond to mean ± standard deviations.

Similar articles

Cited by

References

    1. Cancer [homepage on the Internet]. Geneva: World Health Organization. Accessed January 15, 2013. Available from: http://www.who.int/cancer/about/facts/en/.
    1. Funkhouser J. Reinventing pharma: the theranostic revolution. Curr. Drug Discovery 2, 17–19 (2002).
    1. Bardhan R., Lal S., Joshi A. & Halas N. J. Theranostic nanoshells: from probe design to imaging and treatment of cancer. Acc. Chem. Res. 44, 936–946 (2011). - PMC - PubMed
    1. Davis M. E., Chen Z. G. & Shin D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discovery 7, 771–782 (2008). - PubMed
    1. Petros R. A. & DeSimone J. M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discovery 9, 615–627 (2010). - PubMed

Publication types